Metastatic renal cell carcinoma (mRCC) is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. Previously, systemic treatment was limited to cytokine therapy [1]. Treatment options have expanded considerably for patients with mRCC with the greater understanding of the molecular mechanisms involved [2–4]. Seven molecular targeted agents for the treatment of mRCC are now approved, with significant improvements in progression-free survival (PFS) but rarely with an impact on overall survival (OS) [5].
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2igy6k2
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
Abstract Unsaturated fatty acid biohydrogenation products from beef fat and pure fatty acids were subjected to the Ames Salmonella mutage...
-
UM-Chor1: establishment and characterization of the first validated clival chordoma cell line. J Neurosurg. 2017 Apr 21;:1-9 Authors:...
-
Publication date: Available online 10 May 2017 Source: Journal of Dairy Science Author(s): R.E. Vibart, M. Tavendale, D. Otter, B.H. Schw...
-
Objectives Early identification of distinct patterns of child social–emotional strengths and vulnerabilities has the potential to improve ou...
-
Related Articles Developmental control of macrophage function. Curr Opin Immunol. 2017 Dec 13;50:64-74 Authors: Bonnardel J, Guillia...
-
Successful immunosuppressant-free heterotopic transplantation of tracheal allografts in the pig. Eur J Cardiothorac Surg. 2017 May 02;...
-
Sexual Science versus Progressive Advocacy: The Need for Resistance Tracking Mouse Trajectories Related to Decisions About Sexual Interest A...
-
Abstract To evaluate genetic variation, 27 accessions of allotetraploid species Aegilops kotschyi and Ae. variabilis with the US genome ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου